Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

ClinicalTrials.gov ID: NCT01185977

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01185977. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will aim to evaluate the use of Electroencephalography (EEG) biomarkers in adolescent depression. Two specific hypotheses will be tested: H1: Early decreases in prefrontal cordance values will be greater in responders to antidepressant therapy than in medication non-responders. H2: Subjects with high Antidepressant Treatment Response(ATR) Index values \[i.e., predicted to show symptomatic improvement with fluoxetine (FLX)\] will achieve greater improvement in symptoms and in functional status than those with low ATR values. Exploratory analyses will be undertaken to compare and contrast the cordance changes and ATR values in medication and placebo-treated responders and non-responders.

Study identification

NCT ID: NCT01185977
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: University of California, Los Angeles; Other
Enrollment: 26 participants

Conditions and interventions

Conditions

Major Depressive Disorder

Interventions

Fluoxetine Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 14 Years to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2010 (Type not available)
Primary completion: Oct 2011 (Actual)
Completion: Not listed
Last update posted: Jul 3, 2014

Started 2010

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
UCLA Semel Institute	Los Angeles	California	90095	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01185977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 3, 2014 · Synced Nov 12, 2026